The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Open accessAbstract
To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. Significance: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. We used a genetic approach to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment. See related commentary by Savona and Rathmell, p. 831. This article is highlighted in the In This Issue feature, p. 813
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“acquired resistance is a central concern with single agent, targeted therapies with many 73 instances now documenting favorable initial responses that give way to disease relapse 74 resulting from loss of drug sensitivities [26].”
BackgroundOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“This overexpression aims to neutralize BH3 domains of apoptotic activators 54 BID, BIM and PUMA, thus preventing liberation of pro-apoptotic proteins BAX/BAK from 55 inhibitory interactions with anti-apoptotic BCL2 family proteins [4-6].”
BackgroundThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593 · cited 10×
“Resistance to Venetoclax Coincides with Protection from Mitochondrial Stress and Increases in Oxidative Phosphorylation The top hits from our CRISPR screen pointed toward perturbations in mitochondrial regulators and effectors of the apoptotic program. p53, BAX, PMAIP1, TFDP1, and BAK function in a proapoptotic manner…”
BackgroundInfluentialA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“It is possible that p53 inactivation also has a transcriptional impact on the observed metabolic changes, because it is known to negatively control glycolysis through the induction of TIGAR expression (45), which degrades fructose-2,6-bisphosphate and opposes the Warburg effect.”
BackgroundThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
Self-citationReactome: a knowledgebase of biological pathways
Joshi-Tope, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki072 · Cited by 1,290
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761 · cited 3×
“Analyses of genome wide CRISPR screen 143 knockouts is challenged by off-targeting, sgRNA guide efficiency, and other factors that can lead 144 to library specific artifacts and striking differences between libraries [31, 33].”
BackgroundSelective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., & Brodeur, G. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303253281205 · Cited by 694
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
The mitochondrial transporter family SLC25: Identification, properties and physiopathology
Palmieri, F. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.005 · Cited by 615
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Self-citationDiagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
Li, P.-F. (1999) · The EMBO Journal · doi:10.1093/emboj/18.21.6027 · Cited by 478
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
Myeloid cell factor–1 is a critical survival factor for multiple myeloma
Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 367
Elesclomol induces cancer cell apoptosis through oxidative stress
Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C.-Y., Zhang, M., Du, Z., Barsoum, J., & Bertin, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0298 · Cited by 353
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis
Hershko, T., & Ginsberg, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312866200 · Cited by 322
Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0758 · Cited by 321
Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300
Fusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25)
Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1355 · Cited by 281
Neurotrophins and the immune system
Vega, J. A., García‐Suárez, O., Hannestad, J., Pérez‐Pérez, M., & Germanà, A. (2003) · Journal of Anatomy · doi:10.1046/j.1469-7580.2003.00203.x · Cited by 268
Apoptosis and oncogenesis: give and take in the BCL-2 family
Llambi, F., & Green, D. R. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.12.001 · Cited by 262
GTRD: a database on gene transcription regulation—2019 update
Yevshin, I., Sharipov, R., Kolmykov, S., Kondrakhin, Y., & Kolpakov, F. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1128 · Cited by 256
Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2005-12-5148 · Cited by 245
In Vivo Detection of Apoptosis
Blankenberg, F. G. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045898 · Cited by 241
Role of mitochondrial permeability transition pores in mitochondrial autophagy
Rodriguez-Enriquez, S., He, L., & Lemasters, J. J. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.04.009 · Cited by 239
Decoding and unlocking the BCL-2 dependency of cancer cells
Juin, P., Geneste, O., Gautier, F., Depil, S., & Campone, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3538 · Cited by 232
Tomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113027 · Cited by 227
Findley, H. W., Gu, L., Yeager, A. M., & Zhou, M. (1997) · Blood · doi:10.1182/blood.v89.8.2986 · Cited by 213
Kim, J., Yu, L., Chen, W., Xu, Y., Wu, M., Todorova, D., Tang, Q., Feng, B., Jiang, L., He, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.012 · Cited by 202
Imazu, T., Shimizu, S., Tagami, S., Matsushima, M., Nakamura, Y., Miki, T., Okuyama, A., & Tsujimoto, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1202722 · Cited by 187
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
Lin, K. H., Winter, P. S., Xie, A., Roth, C., Martz, C. A., Stein, E. M., Anderson, G. R., Tingley, J. P., & Wood, K. C. (2016) · Scientific Reports · doi:10.1038/srep27696 · Cited by 186
Expression of Neurotrophins and their Receptors in Human Bone Marrow
Labouyrie, E., Dubus, P., Groppi, A., Mahon, F. X., Ferrer, J., Parrens, M., Reiffers, J., de Mascarel, A., & Merlio, J. P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65287-x · Cited by 171
Nemkov, T., D’Alessandro, A., & Hansen, K. C. (2015) · Amino Acids · doi:10.1007/s00726-015-2019-9 · Cited by 163
Self-citationClinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Zhang, H., Savage, S. L., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08263-x · Cited by 158
Self-citationTognon, C. E., Garnett, M. J., Kenward, E., Kay, R., Morrison, K. B., & Sorensen, P. H. B. (2001) · PubMed · Cited by 154
Self-citationTaipale, M., Krykbaeva, I., Whitesell, L. J., Santagata, S., Zhang, J., Liu, Q., Gray, N. S., & Lindquist, S. L. (2013) · Nature Biotechnology · doi:10.1038/nbt.2620 · Cited by 128
Phillips, D. C., Xiao, Y., Lam, L. T., Litvinovich, E., Roberts-Rapp, L. A., Souers, A. J., & Leverson, J. D. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.88 · Cited by 123
Reuther, G. W., Lambert, Q. T., Caligiuri, M. A., & Der, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8655-8666.2000 · Cited by 120
Chevalier, S., Praloran, V., Smith, C., MacGrogan, D., Ip, N. Y., Yancopoulos, G. D., Brachet, P., POUPLARD, A., & Gascan, H. (1994) · Blood · doi:10.1182/blood.v83.6.1479.1479 · Cited by 96
アミノ酸代謝の阻害はヒト白血病幹細胞を選択的に標的とする【JST・京大機械翻訳】
Courtney, L., Brett, M. S., Angelo, D., Julie, A. R., Culp‐Hill, R., Travis, N., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · Cited by 96
Self-citationHasegawa, H., Yamada, Y., Iha, H., Tsukasaki, K., Nagai, K., Atogami, S., Sugahara, K., Tsuruda, K., Ishizaki, A., & Kamihira, S. (2009) · Leukemia · doi:10.1038/leu.2009.171 · Cited by 84
Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis
Prokesch, A., Graef, F. A., Madl, T., Kahlhofer, J., Heidenreich, S., Schumann, A., Moyschewitz, E., Pristoynik, P., Blaschitz, A., Knauer, M., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600845r · Cited by 75
Acquired resistance to venetoclax (ABT-199) int(14;18)positive lymphoma cells
Bodo, J., Zhao, X., Durkin, L. M., Souers, A. J., Phillips, D. C., Smith, M. R., & Hsi, E. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12132 · Cited by 69
High-affinity neurotrophin receptors and ligands promote leukemogenesis
Li, Z., Beutel, G., Rhein, M., Meyer, J., Koenecke, C., Neumann, T., Yang, M., Krauter, J., Neuhoff, N. V., Heuser, M., et al. (2008) · Blood · doi:10.1182/blood-2008-05-155200 · Cited by 59
Lannon, C. L., Martin, M. J., Tognon, C. E., Jin, W., Kim, S., & Sorensen, P. H. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307388200 · Cited by 55
Self-citationOncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Taylor, J., Pavlick, D. C., Yoshimi, A., Marcelus, C., Chung, S. S., Hechtman, J. F., Benayed, R., Cocco, E., Durham, B. H., Bitner, L. E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120787 · Cited by 55
Study of PTPC Composition during Apoptosis for Identification of Viral Protein Target
Verrier, F., Mignotte, B., Jan, G., & Brenner, C. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1299.022 · Cited by 52
Smith, K. M., Fagan, P. C., Pomari, E., Germanò, G., Frasson, C., Walsh, C. T., Silverman, I. M., Bonvini, P., & Li, G. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0419 · Cited by 42
Detecting and targetting oncogenic fusion proteins in the genomic era
Davare, M. A., & Tognon, C. E. (2015) · Biology of the Cell · doi:10.1111/boc.201400096 · Cited by 37
Self-citationWoo, I. S., Jin, H., Kang, E. S., Kim, H. J., Lee, J. H., Chang, K. C., Park, J., Choi, W. S., & Seo, H. G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.05.031 · Cited by 36
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia
Edelmann, J., & Gribben, J. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.023291 · Cited by 23
Roles of AML 1/ RUNX 1 in T‐cell malignancy induced by loss of p53
Shimizu, K., Yamagata, K., Kurokawa, M., Mizutani, S., Tsunematsu, Y., & Kitabayashi, I. (2013) · Cancer Science · doi:10.1111/cas.12199 · Cited by 16
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
DiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 679
Pei, S., Pollyea, D. A., Gustafson, A., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0710 · Cited by 562
Self-citationThe BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Metadata
- Authors
- Nechiporuk, T., Kurtz, S. E., Nikolova, O., Liu, T., Jones, C. L., D'Alessandro, A., Culp-Hill, R., d'Almeida, A., Joshi, S. K., Rosenberg, M., Tognon, C. E., Danilov, A. V., Druker, B. J., Chang, B. H., McWeeney, S. K., & Tyner, J. W.
- Venue
- Cancer Discovery
- Published
- 2019-07-01
- Volume
- 9
- Issue
- 7
- Pages
- 910-925
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2942538710
- Cited by
- 378
- References
- 84
- FWCI
- 24.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.